European Journal Of Haematology · 2018 · 32 citations · 39 references
MedicineOncologyChemotherapyHematologic OncologyNeoplasiaCancer StagingLymphoid NeoplasmsLymphoid TumorsMalignant NeoplasmsDisease-free Survival AnalysisDisease-free Survival AssessmentHemophagocytosis In Bone MarrowLymphoma StagingMedian AgeNatural Killer T-cell LymphomaNatural Killer-cell LymphomaPrognostic Factors Analysis
OBJECTIVES: We aimed to define the clinical features, outcome, and prognostic factors for extranodal NK/T-cell lymphoma (ENKTL) patients in Taiwan. METHODS: We retrospectively reviewed 101 ENKTL patients diagnosed between February 1998 and October 2015. RESULTS: The median age of 101 patients was 52 years old (range 22-85); 76.2% of patients were Ann Arbor stage I/II disease. The 5-year progression-free survival (PFS) and overall survival (OS) were 49.9% and 54.8%, respectively. Patients with log[EBV-DNA] ≥ 3.8 and bone marrow hemophagocytosis at diagnosis had inferior PFS and OS. Most stage I/II patients received combined chemoradiotherapy with anthracycline-containing regimen, with overall response rate of 96.7%, complete response rate 86.9%, 5-year PFS 65%, and OS 72%. The relapse rate was 29.3% with a short median disease-free survival of 6.2 months. In advanced stage patients, overall response rate was only 13.6%, with median PFS 2.3 months, and OS 4.8 months. Age ≥ 60 (HR 3.773, 95% CI 1.733-8.215, P = 0.001) and stage III/IV (HR 7.785, 95% CI 2.312-26.213, P = 0.001) were unfavorable prognostic factors for PFS and OS by multivariate analyses. CONCLUSIONS: Age ≥ 60 and stage III/IV are independent poor prognostic factors for PFS and OS. Early-stage ENKTL patients had good response to combined chemoradiotherapy with anthracycline-containing regimen but with a high relapse rate and short disease-free survival. Anthracycline-containing regimen in advanced stage had poor response and dismal outcome.
39
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
New England Journal of Medicine · 1993 · 5K citations · Full text
Medicine, Oncology, Chemotherapy +15
Revised Response Criteria for Malignant Lymphoma
Bruce D. Cheson, Beate Pfistner, Malik E. Juweid et al. · Journal of Clinical Oncology · 2007 · 4.4K citations · Full text
A predictive model for aggressive non-Hodgkin's lymphoma
Margaret A. Shipp, David P. Harrington, J R Anderson et al. · 1993 · 3.5K citations
Medicine, Oncology, Chemotherapy +15
Motoko Yamaguchi, Yok‐Lam Kwong, Won Seog Kim et al. · Journal of Clinical Oncology · 2011 · 602 citations
Pharmacy, Oncology, Pharmacotherapy +13